Autres langues Orphazyme A/S

Actions

Temps Différé Nasdaq Copenhagen Autres places de cotation 09:59:03 29/04/2024			Varia. 5j.	Varia. 1 janv.
976,8 ^DKK	-10,39%		-2,81%	-26,56%

27/03	Orphazyme A/S publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
21/02	Orphazyme A/S (CPSE:ORPHA) a acquis une participation minoritaire supplémentaire inconnue dans CombiGene AB (publ) (OM:COMBI).	CI

STALICLA Appoints Dr. Thomas Blaettler, MD	12/04
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
FDA Extends Review of Zevra's Arimoclomol by Three Months	04/03
BioStock: Comments from Orphazyme on the investment in CombiGene	04/03
The Danish company Orphazyme has acquired 10% of the shares in CombiGene	21/02
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	21/02
Zevra Therapeutics Refiles Arimoclomol Application With FDA	27/12
Myositis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	10/10/23
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)	28/09/23
Orphazyme A/S Provides Earnings Guidance for the Full Year 2023	12/09/23
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2023	12/09/23
Change in management	30/05/23
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CEO	30/05/23
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO	30/05/23
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	30/05/23
Major shareholder announcement	19/05/23
Major shareholder announcement	17/05/23
Resolutions passed at the Annual General Meeting	17/05/23
Changes to the Board of Directors	17/05/23
Changes to the Board of Directors	17/05/23

Aucun résultat pour cette recherche